Last month, we had Eyes On some of the latest approvals, M&A and litigation. Read more about AbbVie, Genentech, Lundbeck, and GSK ...

Eye's on the Amgen data releases for gMG & Atopic Dermatitis, the BMS approval of Cobenfy for schizophrenia, and Pfizer's Oxbryta recall...

This month, we've had Eyes on investment trends, strategic restructuring, and FDA decisions. Fall seems to be gearing up, and we can't wait

We've had our Eyes On some of the latest Pharmaceutical news including approvals, partnering, mergers, research programs, and

News & Views - sharing some oncology, AZD, M&A tidbits that caught our eye.

his week we've been looking at the competition heating up due to a combination of M&A, biosimilar entrants, and new clinical data ...